drugset
drugset / Trial / NCT00678652

Phase 1 Safety and Immunogenicity of Meningococcal Vaccine

NCT00678652 ↗

Phase 1 Completed 36 enrolled U.S. Army Medical Research and Development Command
Non-randomizedSingle-groupOpen-labelPrevention

Summary

The purpose of this study is to determine whether a vaccine based on outer membrane vesicles (NOMV) from genetically detoxified group B meningococcus is safe and effective for use as a vaccine. If so, the NOMV in this vaccine will be combined with NOMV from two other genetically modified strains as a potentially globally effective vaccine against group B meningococcus.

Timeline

Start
2008-04
Primary completion
2009-08
Completion
2009-08

Drugs

EvaluationDrugModalityDoseRoute
Subject Group B Meningococcal 8570 HOPS-G NOMV Vaccine Vaccine 10 ug Intramuscular
Subject Group B Meningococcal 8570 HOPS-G NOMV Vaccine Vaccine 25 ug Intramuscular
Subject Group B Meningococcal 8570 HOPS-G NOMV Vaccine Vaccine 50 ug Intramuscular
Subject Group B Meningococcal 8570 HOPS-G NOMV Vaccine Vaccine 75 ug Intramuscular

Indications

meningococcal infection